CTOs on the Move

Advarra

www.advarra.com

 
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.advarra.com
  • 6100 Merriweather Drive Suite 600
    Columbia, MD USA 21044
  • Phone: 410.884.2900

Executives

Name Title Contact Details
Jeff Sidell
Chief Technology Officer Profile
Eric Whitford
IT Director Profile
Nitin Uplekar
Chief Information Officer Profile
Jonathan Shough
President of Technology Solutions Profile

Jobs

Similar Companies

Jerome Stevens Pharmaceuticals

Jerome Stevens Pharmaceuticals is a Bohemia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chalmers and Kubeck North

Chalmers and Kubeck North is a Salem, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Javan Engineering Inc

Javan Engineering Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.